Visceral adipose tissue in patients with Crohn's disease correlates with disease activity, inflammatory markers, and outcome

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2590-2597

  Büning, Carsten ^a,b   Von Kraft, Christian ^b   Hermsdorf, Mario ^c   Gentz, Enno ^a,b   Wirth, Eva K ^b   Valentini, Luzia ^d   Haas, Verena ^b  

^a Krankenhaus Waldfriede   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Hochschule Neubrandenburg   (Germany)

Author keywords

Crohn's disease; disease activity; visceral adipose tissue

Indexed keywords

ADALIMUMAB; ADIPONECTIN; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BIOLOGICAL MARKER; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN;

ABDOMINAL WALL THICKNESS; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FAT MASS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; INFLAMMATION; INTRAABDOMINAL FAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REAL TIME ULTRASOUND SCANNER; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ULTRASOUND TRANSDUCER; VISCERAL ADIPOSE TISSUE FAT MASS RATIO; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; YOUNG ADULT;

ADULT; BODY COMPOSITION; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LEPTIN; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84945277294     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000527     Document Type: Article

References (23)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.
2. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583-590.
3. Fink C, Karagiannides I, Bakirtzi K, et al. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2012;18:1550-1557.
4. Schaffler A, Herfarth H. Creeping fat in Crohn's disease: travelling in a creeper lane of research? Gut. 2005;54:742-744.
5. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999;117:73-81.
6. Katznelson L, Fairfield WP, Zeizafoun N, et al. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab. 2003;88:5468-5472.
7. Gong WK, Ren HL, Tong HZ, et al. A comparison of ultrasound and magnetic resonance imaging to assess visceral fat in the metabolic syndrome. Asia Pac J Clin Nutr. 2007;16:339-345.
8. Dignass A, Van AG, Lindsay JO, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
9. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
10. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
11. Vogt FM, Ruehm S, Hunold P, et al. Rapid total body fat measurement by magnetic resonance imaging: quantification and topography [in German]. Rofo. 2007;179:480-486.
12. Bryant RV, Trott MJ, Bartholomeusz FD, et al. Systematic review: body composition in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:213-225.
13. Jahnsen J, Falch JA, Mowinckel P, et al. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2003;98:1556-1562.
14. Geerling BJ, Lichtenbelt WD, Stockbrugger RW, et al. Gender specific alterations of body composition in patients with inflammatory bowel disease compared with controls. Eur J Clin Nutr. 1999;53:479-485.
15. Batra A, Heimesaat MM, Bereswill S, et al. Mesenteric fat-control site for bacterial translocation in colitis? Mucosal Immunol. 2012;5:580-591.
16. Erhayiem B, Dhingsa R, Hawkey CJ, et al. Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:684-687.
17. Uko V, Vortia E, Achkar JP, et al. Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease. Inflamm Bowel Dis. 2014;20:2286-2291.
18. Mendall MA, Gunasekera AV, John BJ, et al. Is obesity a risk factor for Crohn's disease? Dig Dis Sci. 2011;56:837-844.
19. Blain A, Cattan S, Beaugerie L, et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr. 2002;21:51-57.
20. Hass DJ, Brensinger CM, Lewis JD, et al. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:482-488.
21. Flores A, Burstein E, Cipher DJ, et al. Obesity in inflammatory bowel disease: a marker of less severe disease. Dig Dis Sci. 2015;60: 2436-2345.
22. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102: 2708-2715.
23. Iacobellis G. Imaging of visceral adipose tissue: an emerging diagnostic tool and therapeutic target. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:345-353.